| 93 | 0 | 113 |
| 下载次数 | 被引频次 | 阅读次数 |
目的 通过调查医务人员对卡瑞利珠单抗安全性的认知现状，为卡瑞利珠单抗的适宜性评价提供依据。方法 采用非概率目的抽样法，于2023年4至9月向湖北省10个城市的部分医疗机构肿瘤专业的300名医务人员（医师、护理人员和药师）发放问卷，调查医务人员对卡瑞利珠单抗药品说明书中的安全性信息的认知现状，以及对免疫相关不良事件（irAEs）和反应性毛细血管增生症（RCCEP）的关注情况。结果 共回收有效问卷204份，有效回收率为68.0%。204名医务人员在对卡瑞利珠单抗药品说明书中安全性信息认同度方面的总得分为3.78±0.69。卡瑞利珠单抗安全性信息获取频率不同的医务人员在安全性信息的认同度得分方面比较差异有统计学意义（P <0.05）。RCCEP是医务人员最关注的irAEs（占57.35%）。对于RCCEP，医务人员比较担心的问题主要有发生并发症而影响用药安全性（占67.16%）、影响正常抗肿瘤治疗进度（占54.90%）和患者产生恐惧心理影响用药依从性（占40.69%）。医务人员期望获取更多关于RCCEP的预防方法（占59.8%）、RCCEP的治疗与护理方法（占59.31%）、RCCEP的危险因素与高危人群筛选方法（占55.39%）方面的信息。结论 医务人员对卡瑞利珠单抗安全性的认知水平整体不高，需扩展医务人员的信息获取渠道，提高医务人员对卡瑞利珠单抗安全性的认知水平，进一步保障临床用药安全。
Abstract：AIM To evaluate the suitability evaluation of camrelizumab by investigating the cognition of medical staff on the safety of camrelizumab. METHODS From April to September of 2023, electronic questionnaires were distributed to oncological doctors, nurses, and pharmacists from more than 10 cities in Hubei Province using non-probabilistic purposeful sampling. It mainly focused on the 3 aspects of health care workers' cognition and evaluation: the cognitive status of security information in the package insert for camrelizumab, concerns about immune-related adverse events(irAEs), and safety of reactive cutaneous capillary endothelial proliferation(RCCEP).RESULTS A total of 204 questionnaires were collected, with an effective recovery rate of 68.0%. The average score of respondents' recognition of the safety information provided by the package insert was(3.78±0.69). Statistically significant differences in the scores of agreement with the safety information were observed among medical staff with different frequencies of obtaining safety information about camrelizumab(P<0.05). RCCEP was the most concerning irAE among medical staff(57.35%). Medical staff were particularly concerned about the impact of complications on medication safety(67.16%), the progress of normal antitumor treatment(54.90%), and the psychological fear affecting medication adherence(40.69%). Medical staff expected to obtain more information on the prevention methods of RCCEP(59.8%), the treatment and nursing methods of RCCEP(59.31%), the risk factors and high-risk population screening methods of RCCEP(55.39%). CONCLUSION The overall level of awareness regarding the safey of camrelizumab among medical staff is relatively low. Medical staff may strengthen the access to drug safety information of camrelizumab to further ensure the safety of clinical medication.
[1]中华人民共和国国家卫生健康委员会.国家卫生健康委办公厅关于规范开展药品临床综合评价工作的通知[EB/OL].(2021-07-30)[2024-05-27]. http://www.nhc.gov.cn/yaozs/s7656/202011/d11d dc32fae84121a0dfca36b015a31d/files/863665c55fd74f29a656990d1a4ea5ce.pdf.
[2]国家药物和卫生技术综合评估中心.抗肿瘤药品临床综合评价技术指南(2022年版试行)[EB/OL].(2022-06-28)[2024-05-29].http://www.nhei.cn/nhei/znfb/202206/c01d87a290664b01bf42a9da d769d69f/files/4e062c199b17474ca680da5aac3b6d89.pdf.
[3] MARKHAM A, KEAM S J. Camrelizumab:first global approval[J]. Drugs, 2019, 79(12):1355.
[4] YI M, ZHENG X L, NIU M K, et al. Combination strategies with PD-1/PD-L1 blockade:current advances and future directions[J].Mol Cancer, 2022, 21(1):28.
[5] HAHN A W, GILL D M, AGARWAL N, et al. PD-1 checkpoint inhibition:Toxicities and management[J]. Urol Oncol, 2017,35(12):701.
[6] NAIDOO J, PAGE D B, LI B T, et al. Toxicities of the anti-PD-1and anti-PD-L1 immune checkpoint antibodies[J]. Ann Oncol,2016, 27(7):1362.
[7]程巧巧,陈冰,张伟霞,等. 1例卡瑞利珠单抗致免疫相关性肝炎病例分析[J].中国临床药学杂志, 2022, 31(11):865.
[8] HUANG A Q, WANG X X, TAO Y, et al. Healthcare professionals'knowledge, attitude and practice towards National Centralized Drug Procurement policy in central China:a cross-sectional study[J]. Front Pharmacol, 2022, 13:996824.
[9] KHAMAS S S, JAFARI A, ZARIF-YEGANEH M, et al. Evaluation of medication package inserts in Iran[J]. J Res Pharm Pract,2019, 8(2):45.
[10] ZHENG Y F, TANG Y, TSENG H C, et al. Evaluation of quality and readability of over-the-counter medication package inserts[J].Res Social Adm Pharm, 2022, 18(9):3560.
[11] HAILU H G, GOBEZIE M Y, TUEM K B, et al. Evaluation of medication package inserts in Ethiopia[J]. J Environ Public Health, 2022, 2022:8299218.
[12] SPAIN L, DIEM S, LARKIN J. Management of toxicities of immune checkpoint inhibitors[J]. Cancer Treat Rev, 2016, 44:51.
[13] WEBER J S, POSTOW M, LAO C D, et al. Management of adverse events following treatment with anti-programmed death-1 agents[J]. Oncologist, 2016, 21(10):1230.
[14] ZHANG W C, YAN C H, GAO X, et al. Safety and feasibility of radiotherapy plus camrelizumab for locally advanced esophageal squamous cell carcinoma[J]. Oncologist, 2021, 26(7):e1110.
[15] LIU J, YANG Y, LIU Z C, et al. Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma[J]. J Immunother Cancer, 2022, 10(3):e004291.
[16] XIA Y X, TANG W W, QIAN X F, et al. Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma:a single-arm, open label,phase II clinical trial[J]. J Immunother Cancer, 2022, 10(4):e004656.
[17] LIU J Q, LIU Q, LI Y, et al. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer:an open-label phase II trial[J]. J Immunother Cancer, 2020,8(1):e000696.
[18] HUANG J, XU J M, CHEN Y, et al. Camrelizumab versus investigator’s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma(ESCORT):a multicentre, randomised, open-label, phase 3 study[J]. Lancet Oncol, 2020, 21(6):832.
[19] REN S X, CHEN J H, XU X X, et al. Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC(CameL-sq):a phase 3 trial[J]. J Thorac Oncol, 2022, 17(4):544.
[20] ZHOU C C, CHEN G Y, HUANG Y C, et al. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous nons m a l l-c e l l l u n g c a n c e r(C a m e L):a r a n d o m i s e d, o p e n-l a b e l,multicentre, phase 3 trial[J]. Lancet Respir Med, 2021, 9(3):305.
[21] ZHANG B C, SONG Y X, FU Y, et al. Current status of the clinical use of PD-1/PD-L1 inhibitors:a questionnaire survey of oncologists in China[J]. BMC Cancer, 2020, 20(1):86.
[22] PANG H M, HUANG G M, QIN X L, et al. Reactive cutaneous capillary endothelial proliferation caused by camrelizumab:sixteen case reports[J]. Indian J Dermatol, 2023, 68(3):318.
[23] LIU Y, CHEN T C, ZHANG C, et al. Emerging treatments for reactive cutaneous capillary endothelial proliferation[J]. Indian J Dermatol, 2023, 68(1):85.
基本信息:
DOI：10.19577/j.1007-4406.2024.11.004
中图分类号:R979.1
引用信息:
[1]张颖佩,王璇璇,程虹.医务人员对卡瑞利珠单抗安全性的认知现状调查[J].中国临床药学杂志,2024,33(11):819-824.DOI:10.19577/j.1007-4406.2024.11.004.
基金信息:
湖北省卫生健康委临床综合评价项目（编号WJ2023F017）